Carotid plaque formation and serum biomarkers

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 21-29

  Hermus, Linda ^a   Lefrandt, Joop D ^a   Tio, René A ^a   Breek, Jan Cees ^b   Zeebregts, Clark J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

Angiogenesis; Biomarker; Carotid artery; Inflammation; Proteolysis; Vulnerable plaque

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UROKINASE;

ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CALCIFICATION; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; HIGH RISK PATIENT; HUMAN; HYPOXIA; INFLAMMATION; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; SERUM; STENT; STROKE; THROMBOSIS;

ANOXIA; APOPTOSIS; BIOLOGICAL MARKERS; CARDIOLOGY; CAROTID ARTERIES; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; HUMANS; INFLAMMATION; LIPIDS; NEOVASCULARIZATION, PATHOLOGIC; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 77958461205     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.05.013     Document Type: Review

References (97)

1. Halvorsen B., Otterdal K., Skjelland M., et al. Atherosclerotic plaque stability-what determines the fate of the plaque?. Prog Cardiovasc Dis 2008, 51(3):183-194.
2. Felton C.V., Crook D., Davies M.J., Oliver M.F. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997, 17(7):1337-1345.
3. Collins R., Armitage J., Parish S., Sleight P., Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high risk conditions. Lancet 2004, 363(9411):757-767.
4. Meisinger C., Baumert J., Khuseyinova N., Loewel H., Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005, 112(5):651-657.
5. Nishi K., Itabe H., Uno M., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22(10):1649-1654.
6. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343(16):1148-1155.
7. Blake G.J., Dada N., Fox J.C., Manson J.E., Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001, 38(5):1302-1306.
8. Wilensky R.L., Shi Y., Mohler E.R., et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008, 14(10):1059-1066.
9. Mannheim D., Herrmann J., Versari D., et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008, 39(5):1448-1455.
10. Mathiesen E.B., Bønaa K.H., Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the tromsø study. Stroke 2001, 32(9):1960-1965.
11. Ohira T., Schreiner P.J., Morrisett J.D., et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006, 37(6):1407-1412.
12. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361(26):2518-2528.
13. Iwamoto T., Fukuda S., Shimizu S., Takasaki M. Long-term effects of lipoprotein(a) on carotid atherosclerosis in elderly Japanese. J Gerontol A Biol Sci Med Sci 2004, 59(1):62-67.
14. Klein J.H., Hegele R.A., Hackam D.G., et al. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 2008, 28(10):1851-1856.
15. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44(12):2737-2745.
16. Rohde L.E., Hennekens C.H., Ridker P.M. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999, 84(9):1018-1022.
17. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843.
18. Berk B.C., Weintraub W.S., Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990, 65(3):168-172.
19. Ridker P.M., Danielson E., Fonseca F.A., et al. JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373(9670):1175-1182.
20. Koenig W., Löwel H., Baumert J., Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004, 109(11):1349-1353.
21. Schillinger M., Exner M., Mlekusch W., et al. Inflammation and Carotid Artery-risk for Atherosclerosis Study (ICARAS). Circulation 2005, 111(17):2203-2209.
22. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attacks: the Framingham Study. Stroke 2001, 32(11):2575-2579.
23. Profumo E., Buttari B., Tosti M.E., et al. Association of intracellular pro- and anti-inflammatory cytokines in peripheral blood with the clinical or ultrasound indications for carotid endarterectomy in patients with carotid atherosclerosis. Clin Exp Immunol 2008, 152(1):120-126.
24. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331(7):417-424.
25. Brea D., Sobrino T., Blanco M., et al. Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. Atherosclerosis 2009, 205(2):561-567.
26. Ishida Y., Migita K., Izumi Y., et al. The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett 2004, 569(1-3):156-160.
27. Mallat Z., Corbaz A., Scoazec A., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104(14):1598-1603.
28. Blankenberg S., Luc G., Ducimetiere P., et al. PRIME Study Group Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003, 108(20):2453-2459.
29. Korshunov V.A., Nikonenko T.A., Tkachuk V.A., Brooks A., Berk B.C. Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intima-media thickening. Arterioscler Thromb Vasc Biol 2006, 26(2):295-300.
30. Koenig W., Khuseyinova N., Baumert J., et al. Increased concentrations of C-reactive protein and Interleukin-6 but not Interleukin-18 are independently associated with incident coronary events in middle-aged men and women. Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006, 26(12):2745-2751.
31. Kerr R., Stirling D., Ludlam C.A. Interleukin 6 and haemostasis. Br J Haematol 2001, 115(1):3-12.
32. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000, 101(12):1372-1378.
33. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
34. Kinlay S., Schwartz G.G., Olsson A.G., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators. Arterioscler Thromb Vasc Biol 2008, 28(1):142-147.
35. Schindhelm R.K., van der Zwan L.P., Teerlink, Scheffer P.G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clin Chem 2009, 55(8):1462-1470.
36. Bayes-Genis A., Conover C.A., Overgaard M.T., et al. Pregnancy associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001, 345:1022-1029.
37. Sangiorgi G., Mauriello A., Bonanno E., et al. Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol 2006, 47(11):2201-2211.
38. Heeschen C., Dimmeler S., Hamm C.W., et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005, 45(2):229-237.
39. Heider P, Pfäffle N, Pelisek J, et al. Is serum pregnancy-associated plasma protein a really a potential marker of atherosclerotic carotid plaque stability? Eur J Vasc Endovasc Surg 2010 [E-pub ahead of print].
40. Cipollone F., Fazia M., Mincione G., et al. Increased expression of transforming growth factor-b1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004, 35(10):2253-2257.
41. Loftus I.M., Naylor A.R., Goodall S., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000, 31(1):40-47.
42. Morgan A.R., Rerkasem K., Gallagher P.J., et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004, 35(6):1310-1315.
43. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32(2):368-372.
44. Inoue T., Kato T., Takayanagi K., et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol 2003, 92(12):1461-1464.
45. Alvarez B., Ruiz C., Chacón P., Alvarez-Sabin J., Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 2004, 40(3):469-475.
46. Rosemberg G.A., Navratil M., Barone F., Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischaemia in rat. J Cereb Blood Flow Metab 1996, 16(3):360-366.
47. Clark A.W., Krekoski C.A., Bou S.S., Chapman K.R., Edwards D.R. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischaemia. Neurosci Lett 1997, 238(1-2):53-56.
48. Lutgens E., Lutgens S.P., Faber B.C., et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006, 113(1):98-107.
49. Sukhova G.K., Zhang Y., Pan J.H., et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 111(6):897-906.
50. Liu J., Sukhova G.K., Yang J.T., et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 2006, 184(2):302-311.
51. Liu J., Ma L., Yang J., et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006, 186(2):411-419.
52. Moreno P.R., Purushothaman K.R., Fuster V., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110(14):2032-2038.
53. Mofidi R., Crotty T.B., McCarthy P., et al. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001, 88(7):945-950.
54. Sluimer J.C., Gasc J.M., van Wanroij J.L., et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008, 51(13):1258-1265.
55. Holm P.W., Slart R.H., Zeebregts C.J., Hillebrands J.L., Tio R.A. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med 2009, 41(4):257-264.
56. Pitsilos S., Hunt J., Mohler E.R., et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003, 90(6):1112-1120.
57. Post S., Peeters W., Busser E., et al. Balance between angiopoetin-1 and angiopoetin-2 is in favour of angiopoetin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008, 45(3):244-250.
58. Aristoteli L.P., Møller H.J., Bailey B., Moestrup S.K., Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006, 184(2):342-347.
59. Willemsen H.M., van der Horst I.C., Nieuwland W., et al. The diagnostic value of soluble CD163 in patients presenting with chest pain. Clin Biochem 2009, 42(16-17):1662-1666.
60. Kietselaar B.L., Reutelingsperger C.P., Heidendal G.A., et al. Noninvasive detection of plaque instability with use of radiolabelled annexin A5 in patients with carotid artery stenosis. New Engl J Med 2004, 350(14):1472-1473.
61. van Tits L.J., van Heerde W.L., van der Vleuten G.M., et al. Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochem Biophys Res Commun 2007, 356(3):674-680.
62. Sayed S., Cockerill G.W., Torsney E., et al. Elevated tissue expression of thrombomodulatory factors correlates with acute symptomatic carotid plaque phenotype. Eur J Vasc Endovasc Surg 2009, 38(1):20-25.
63. Spagnoli L.G., Mauriello A., Sangiorgi G., et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004, 292(15):1845-1852.
64. Bostrom K., Watson K.E., Horn S., et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993, 91(4):1800-1809.
65. Hirota S., Imakita M., Kohri K., et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993, 143(4):1003-1008.
66. Shanahan C.M., Cary N.R., Metcalfe J.C., Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994, 93(6):2393-2402.
67. O'Brien E.R., Garvin M.R., Stewart D.K., et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994, 14(10):1648-1656.
68. Hunt J.L., Fairman R., Mitchell M.E., et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002, 33(5):1214-1219.
69. Raggi P., Cooil B., Shaw L.J., et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003, 92(7):827-829.
70. Ehara S., Kobayashi Y., Yoshiyama M., et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004, 110(22):3424-3429.
71. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109(18):2175-2180.
72. Kurata M., Okura T., Watanabe S., Fukuoka T., Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond) 2006, 111(5):319-324.
73. Ohmori R., Momiyama Y., Taniguchi H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170(2):333-337.
74. Kadoglou N.P.E., Gerasimidis T., Golemati S., et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 2008, 47(1):55-62.
75. Abedin M., Tintut Y., Demer L.L. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004, 24(7):1161-1170.
76. Virmani R., Ladich E.R., Burke A.P., Kolodgie F.D. Histopathology of carotid atherosclerotic disease. Neurosurgery 2006, 59(5 Suppl. 3):S219-S227.
77. Burke A.P., Kolodgie F.D., Farb A., et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001, 103(7):934-940.
78. Kolodgie F.D., Gold H.K., Burke A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003, 349(24):2316-2325.
79. Mocco J., Choudhri T.F., Mack W.J., et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 2001, 48(4):718-721.
80. Loftus I.M., Naylor A.R., Bell P.R., Thompson M.M. Plasma MMP-9-a marker of carotid plaque instability. Eur J Vasc Endovasc Surg 2001, 21(1):17-21.
81. Alvarez Garcia B., Ruiz C., Chacon P., Sabin J.A., Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg 2003, 38(5):1018-1024.
82. Sapienza P., di Marzo L., Borrelli V., et al. Metalloproteinases and their inhibitors are markers of plaque instability. Surgery 2005, 137(3):355-363.
83. Addabbo F., Mallamaci F., Leonardis D., et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 2007, 22(12):3521-3526.
84. Taurino M., Raffa S., Mastroddi M., et al. Metalloproteinase expression in carotid plaque and its correlation with plasma levels before and after carotid endarterectomy. Vasc Endovasc Surg 2007, 41(6):516-521.
85. Yu Z.Z., Ni Z.H., Gu L.Y., et al. Adiponectin is related to carotid artery plaque and a predictor of cardiovascular outcome in a cohort of non-diabetic peritoneal dialysis patients. Blood Purif 2008, 26(4):386-393.
86. Debing E., Peeters E., Demanet C., De Waele M., Van den Brande P. Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a case-control study. Vasc Endovasc Surg 2008, 42(2):122-127.
87. Koutouzis M., Rallidis L.S., Peros G., et al. Serum interleukin-6 is elevated in symptomatic carotid bifurcation disease. Acta Neurol Scand 2009, 119(2):119-125.
88. Sapienza P., Borrelli V., di Marzo L., Cavallaro A. MMP and TIMP alterations in asymptomatic and symptomatic severe recurrent carotid artery stenosis. Eur J Vasc Endovasc Surg 2009, 37(5):525-530.
89. Elkind M.S., Cheng J., Boden-Albala B., et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 2002, 33(1):31-37.
90. Chapman C.M., Beilby J.P., McQuillan B.M., Thompson P.L., Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 2004, 35(7):1619-1624.
91. Ambrosius W., Kazmierski R., Michalak S., Kozubski W. Anti-inflammatory cytokines in subclinical carotid atherosclerosis. Neurology 2006, 66(12):1946-1948.
92. Halvorsen D.S., Johnsen S.H., Mathiesen E.B., Njølstad I. The association between inflammatory markers and carotid atherosclerosis is sex dependent: the Tromsø Study. Cerebrovasc Dis 2009, 27(4):392-397.
93. Handberg A., Skjelland M., Michelsen A.E., et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke 2008, 39(11):3092-3095.
94. Heider P., Pelisek J., Poppert H., Eckstein H.H. Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease. Vasc Endovasc Surg 2009, 43(6):551-560.
95. Pelisek J., Rudelius M., Zepper P., et al. Multiple biological predictors for vulnerable carotid lesions. Cerebrovasc Dis 2009, 28(6):601-610.
96. Olson F.J., Thurison T., Ryndel M., Høyer-Hansen G., Fagerberg B. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem 2010, 43(1-2):124-130.
97. Sugioka K., Naruko T., Hozumi T., et al. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris. Atherosclerosis 2010, 208(2):524-530.